top of page
Title_Background.png

GF-103

GF-103 is an oral first-in-class enzyme therapeutic targeting wet-AMD and inflammatory conditions. This innovative protein drug offers a novel oral delivery platform with applications across multiple indications including mucositis, DME, and IBD.

Pipeline_GF103_MOA1.png

GF-103 is a first-in-class oral MnSOD enzyme therapeutic that targets the root cause of multiple inflammatory diseases. Unlike conventional symptomatic treatments that focus on downstream molecular pathways, GF-103 addresses pathological reactive oxygen species (ROS) generated in the small and large intestines during inflammatory conditions.

Pipeline_GF103_MOA2.png
bottom of page